61 participants
Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for Patients With Relapsed and Refractory Multiple Myeloma Previously Treated With Daratumumab, Lenalidomide and Bortezomib
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-08-11
- Start Date:
- 2021-03-25
- Completion:
- 2027-09-01
Conditions
- Multiple Myeloma in Relapse
- Refractory Multiple Myeloma
Interventions
- DRUG
No Results Yet